Jonathan Young - 01 Mar 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
01 Mar 2024
Net transactions value
+$51,242
Form type
4
Filing time
05 Mar 2024, 17:16:11 UTC
Previous filing
29 Dec 2023
Next filing
15 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $51,242 +83,321 +45% $0.6150* 268,957 01 Mar 2024 Direct F1
holding AKRO Common Stock 20,000 01 Mar 2024 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 01 Mar 2024 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 01 Mar 2024 By JL Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -83,321 -100% $0.000000* 0 01 Mar 2024 Common Stock 83,321 $0.6150 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The options are vested and currently exercisable.